×
Telesis Bio Net Profit Margin 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Telesis Bio net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Telesis Bio Net Profit Margin 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Telesis Bio net profit margin from 2021 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141.6B
Bristol Myers Squibb (BMY)
$116.3B
Gilead Sciences (GILD)
$115.4B
Vertex Pharmaceuticals (VRTX)
$102.3B
CSL (CSLLY)
$83.8B
Regeneron Pharmaceuticals (REGN)
$77.1B
GSK (GSK)
$69.6B
Argenex SE (ARGX)
$37.7B
Alnylam Pharmaceuticals (ALNY)
$31.7B
BioNTech SE (BNTX)
$27.1B
Illumina (ILMN)
$21.6B
Biogen (BIIB)
$21.3B
BeiGene (BGNE)
$17.2B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.4B
Incyte (INCY)
$13.3B
Insmed (INSM)
$12.6B
BioMarin Pharmaceutical (BMRN)
$12.5B
Bio-Techne Corp (TECH)
$11.6B
Sarepta Therapeutics (SRPT)
$11.4B
Exact Sciences (EXAS)
$11B
Vaxcyte (PCVX)
$10.8B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
Exelixis (EXEL)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.3B
Repligen (RGEN)
$8.1B